


Safeguarding Patients With HR+, HER2-, High-Risk, Early Breast Cancer

A Practical Roadmap for *CDK4/6 Inhibition in the Adjuvant Setting*



CME/MOC/CPD/NCPD/CPE/AAPA-Certified Live Symposium

This activity is supported by an educational grant from Lilly.

Thursday, 16 May 2024
12:45-13:45 CEST

hub 27 – Messe Berlin
Munich Hall, Berlin, Germany



CHAIR

Professor Stephen Johnston, MA, PhD
The Royal Marsden NHS Foundation Trust &
The Institute of Cancer Research
Chelsea, London, United Kingdom



PRESENTER

Patrick Neven, MD, PhD
Multidisciplinary Breast Centre
University Hospitals
Leuven, Belgium



PRESENTER

Joyce O'Shaughnessy, MD
Baylor University Medical Center
Dallas, Texas

Agenda

- 12:15 PM CEST: Check-In & Lunch
- 12:45 PM CEST: Symposium
 - Welcome, Introduction, and Educational Goals
 - Conducting Risk Assessment in HR+, HER2- EBC to Identify Patients at High Risk of Recurrence
 - Integrating the Latest Evidence and Guideline Recommendations to Support Multifactorial Clinical Decisions About Adjuvant CDK4/6 Inhibition
 - Mitigating Adverse Events, Improving Adherence/Persistence, and Maximizing Treatment Benefits From CDK4/6 Inhibitors
 - Conclusions and Audience Q&A
- 13:45 PM CEST: Adjourn

Key Reasons to Attend:

- Identify more patients with HR+, HER2- EBC who may benefit from adjuvant CDK4/6 inhibitor therapy to reduce risk of recurrence
- Personalize your treatment plans based on the latest evidence, guideline recommendations, and patient preferences
- Hone your team-based strategies to improve treatment adherence/persistence, adverse event mitigation, and patient education